Xcyte Therapies, Inc. (XCYT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xcyte Therapies, Inc. (XCYT)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: tuck who wrote (15)	7/2/2007 12:14:01 AM
From: kenhott	of 16

I know a little about CYCC. 96.5% because I find it interesting that they are running an adaptive trial for Seliciclib phase 2 (Appraise) in NSCLC, 3rd line, randomized vs. Best Care. Data 4Q2007. They will start with n=160 and for patients with stable or better after 3 cycles on drug, they are randomized to drug or best care. Also they have Sapacilabine (like a Gemcitabine) in phase 2 CTCL open trial, randomized 2 arms, high and low dose drug. They also suppose to have Sap in phase 2 in some sort of solid tumor trial with data expected 4Q2007 but I know next to nothing about that. Re: Aurora target, there are patent issues in EU and US.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext